Author |
Razavi, H.
![]() Waked, I. ![]() Sarrazin, C. ![]() Myers, R. P. ![]() Idilman, R. ![]() Calinas, F. ![]() Vogel, W. ![]() Mendes Correa, M. C. ![]() Hezode, C. ![]() Lazaro, P. ![]() Akarca, U. ![]() Aleman, S. ![]() Balik, I. ![]() Berg, T. ![]() Bihl, F. ![]() Bilodeau, M. ![]() Blasco, A. J. ![]() Brandao Mello, C. E. ![]() Bruggmann, P. ![]() Buti, M. ![]() Calleja, J. L. ![]() Cheinquer, H. ![]() Christensen, P. B. ![]() Clausen, M. ![]() Coelho, H. S. M. ![]() Cramp, M. E. ![]() Dore, G. J. ![]() Doss, W. ![]() Duberg, A. S. ![]() El-Sayed, M. H. ![]() Ergor, G. ![]() Esmat, G. ![]() Falconer, K. ![]() Felix, J. ![]() Ferraz, Maria Lucia Gomes ![]() ![]() Ferreira, Paulo Roberto ![]() ![]() Frankova, S. ![]() Garcia-Samaniego, J. ![]() Gerstoft, J. ![]() Giria, J. A. ![]() Goncales, F. L. ![]() Gower, E. ![]() Gschwantler, M. ![]() Guimaraes Pessoa, M. ![]() Hindman, S. J. ![]() Hofer, H. ![]() Husa, P. ![]() Kaberg, M. ![]() Kaita, K. D. E. ![]() Kautz, A. ![]() Kaymakoglu, S. ![]() Krajden, M. ![]() Krarup, H. ![]() Laleman, W. ![]() Lavanchy, D. ![]() Marinho, R. T. ![]() Marotta, P. ![]() Mauss, S. ![]() Moreno, C. ![]() Murphy, K. ![]() Negro, F. ![]() Nemecek, V. ![]() Ormeci, N. ![]() Ovrehus, A. L. H. ![]() Parkes, J. ![]() Pasini, K. ![]() Peltekian, K. M. ![]() Ramji, A. ![]() Reis, N. ![]() Roberts, S. K. ![]() Rosenberg, W. M. ![]() Roudot-Thoraval, F. ![]() Ryder, S. D. ![]() Sarmento-Castro, R. ![]() Semela, D. ![]() Sherman, M. ![]() Shiha, G. E. ![]() Sievert, W. ![]() Sperl, J. ![]() Starkel, P. ![]() Stauber, R. E. ![]() Thompson, A. J. ![]() Urbanek, P. ![]() Van Damme, P. ![]() van Thiel, I. ![]() Van Vlierberghe, H. ![]() Vandijck, D. ![]() Wedemeyer, H. ![]() Weis, N. ![]() Wiegand, J. ![]() Yosry, A. ![]() Zekry, A. ![]() Cornberg, M. ![]() Muellhaupt, B. ![]() Estes, C. ![]() |
Institution | Ctr Dis Anal Natl Liver Inst JW Goethe Univ Hosp Univ Calgary Ankara Univ Hosp Santo Antonio Capuchos Med Univ Innsbruck Universidade de São Paulo (USP) Hop Henri Mondor Adv Tech Hlth Serv Res TAISS Ege Univ Karolinska Inst Karolinska Univ Hosp Univ Leipzig Osped Cantonale Univ Montreal Fed Univ State Rio de Janeiro Arud Ctr Addict Med Hosp Valle de Hebron Hosp Puerta Hierro Univ Fed Rio Grande do Sul Odense Univ Hosp Reg Hosp Hovedstaden Universidade Federal do Rio de Janeiro (UFRJ) Univ Plymouth Univ New S Wales Cairo Univ Orebro Univ Hosp Univ Orebro Ain Shams Univ Dokuz Eylul Univ Exigo Consultores Universidade Federal de São Paulo (UNIFESP) Inst Clin & Expt Med Hosp Carlos III Univ Copenhagen Direccao Geral Saude Universidade Estadual de Campinas (UNICAMP) Wilhelminenspital Stadt Wien Med Univ Vienna Masaryk Univ Univ Manitoba Hlth Sci Ctr European Liver Patients Assoc Istanbul Univ Univ British Columbia Aalborg Univ Hosp Katholieke Univ Leuven Hosp Santa Maria Univ Western Ontario Univ Dusseldorf Univ Libre Brussels Univ Hosp Natl Inst Publ Hlth Univ Southhampton Dalhousie Univ & Hepatol Serv Assembleia Republ Alfred Hosp Monash Univ UCL Nottingham Univ Hosp NHS Trust Biomed Res Unit Ctr Hosp Porto Cantonal Hosp St Gallen Univ Toronto Egyptian Liver Res Inst & Hosp Monash Hlth Catholic Univ Louvain Med Univ Graz St Vincents Hosp Univ Melbourne Charles Univ Prague Cent Mil Hosp Univ Antwerp Deutsch Leberhilfe eV Ghent Univ Hosp Univ Ghent Hannover Med Sch Copenhagen Univ Hosp Univ Zurich Hosp |
Abstract | The disease burden of hepatitis C virus (HCV) is expected to increase as the infected population ages. A modelling approach was used to estimate the total number of viremic infections, diagnosed, treated and new infections in 2013. in addition, the model was used to estimate the change in the total number of HCV infections, the disease progression and mortality in 2013-2030. Finally, expert panel consensus was used to capture current treatment practices in each country. Using today's treatment paradigm, the total number of HCV infections is projected to decline or remain flat in all countries studied. However, in the same time period, the number of individuals with late-stage liver disease is projected to increase. This study concluded that the current treatment rate and efficacy are not sufficient to manage the disease burden of HCV. Thus, alternative strategies are required to keep the number of HCV individuals with advanced liver disease and liver-related deaths from increasing. |
Keywords |
HCV
diagnosis treatment hepatitis C prevalence epidemiology disease burden mortality incidence |
Language | English |
Sponsor | Gilead Sciences |
Date | 2014-05-01 |
Published in | Journal of Viral Hepatitis. Hoboken: Wiley-Blackwell, v. 21, p. 34-59, 2014. |
ISSN | 1352-0504 (Sherpa/Romeo, impact factor) |
Publisher | Wiley-Blackwell |
Extent | 34-59 |
Origin |
|
Access rights | Open access ![]() |
Type | Article |
Web of Science ID | WOS:000333893200003 |
URI | http://repositorio.unifesp.br/handle/11600/37688 |
File | Size | Format | View |
---|---|---|---|
There are no files associated with this item. |